P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.

摘要: Previous reports on osteosarcomas treated with multi-agent chemotherapy have shown that P-glycoprotein expression is a reliable prognostic indicator. The current thinking that, of the several agents used for treatment osteosarcoma, only doxorubicin involved in drug resistance mediated by P-glycoprotein. This study examines relationship to clinical outcome osteosarcomas, addition surgery, determine if significance reflects ability osteosarcoma respond this drug. tumor specimens was assessed immunohistochemistry 37 nonmetastatic, operable at single institution as adjuvant status analysed relation length event-free survival. A widespread pattern cells diagnosis significantly associated higher rate systemic relapse (p < 0.001). On comparison group patients similar series 92 patients, all plus surgery primary lesion and previously status, P-glycoprotein-positive, doxorubicin-resistant tumors consistently benefited from drugs other than Osteosarcomas different abilities can be identified onset. may serve basis risk-adapted, individualized therapeutic regimens. Standard programs are sufficient P-glycoprotein-negative whereas P-glycoprotein-positive benefit use more intensive approaches.